Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.

Van Kaer L.

Nat Rev Immunol. 2005 Jan;5(1):31-42. Review.

PMID:
15630427
2.

Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.

Wilson MT, Van Kaer L.

Curr Pharm Des. 2003;9(3):201-20. Review.

PMID:
12570826
3.

Immunoregulation of autoimmunity by natural killer T cells.

Linsen L, Somers V, Stinissen P.

Hum Immunol. 2005 Dec;66(12):1193-202. Epub 2006 Mar 31. Review.

PMID:
16690406
4.

iNKT-cell responses to glycolipids.

Parekh VV, Wilson MT, Van Kaer L.

Crit Rev Immunol. 2005;25(3):183-213. Review.

PMID:
16048435
5.

Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia.

Liu R, La Cava A, Bai XF, Jee Y, Price M, Campagnolo DI, Christadoss P, Vollmer TL, Van Kaer L, Shi FD.

J Immunol. 2005 Dec 15;175(12):7898-904.

6.

Natural killer T cells and autoimmune disease.

Wu L, Van Kaer L.

Curr Mol Med. 2009 Feb;9(1):4-14. Review.

PMID:
19199937
7.

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.

Wu L, Gabriel CL, Parekh VV, Van Kaer L.

Tissue Antigens. 2009 Jun;73(6):535-45. doi: 10.1111/j.1399-0039.2009.01256.x. Epub 2009 Apr 8. Review.

PMID:
19392798
9.

Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.

Godó M, Sessler T, Hamar P.

Curr Med Chem. 2008;15(18):1778-87. Review.

PMID:
18691038
10.

NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease.

Yamamura T, Miyamoto K, Illés Z, Pál E, Araki M, Miyake S.

Curr Top Med Chem. 2004;4(5):561-7. Review.

PMID:
14965307
11.

Natural killer T cells as targets for immunotherapy of autoimmune diseases.

Van Kaer L.

Immunol Cell Biol. 2004 Jun;82(3):315-22. Review.

12.

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity.

Wilson SB, Delovitch TL.

Nat Rev Immunol. 2003 Mar;3(3):211-22. Review.

PMID:
12658269
13.

The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.

Pyz E, Naidenko O, Miyake S, Yamamura T, Berberich I, Cardell S, Kronenberg M, Herrmann T.

J Immunol. 2006 Jun 15;176(12):7447-55.

14.

Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.

Sullivan BA, Kronenberg M.

J Clin Invest. 2005 Sep;115(9):2328-9.

15.

Role of invariant natural killer T cells in immune regulation and as potential therapeutic targets in autoimmune disease.

Van Kaer L.

Expert Rev Clin Immunol. 2006 Sep;2(5):745-57. doi: 10.1586/1744666X.2.5.745.

PMID:
20477630
16.

Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation.

Wang J, Cho S, Ueno A, Cheng L, Xu BY, Desrosiers MD, Shi Y, Yang Y.

J Immunol. 2008 Aug 15;181(4):2438-45. Erratum in: J Immunol. 2008 Oct 15;181(8):5803. Xu, Bo-You [corrected to Xu, Bao-You].

17.

Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway.

Miellot A, Zhu R, Diem S, Boissier MC, Herbelin A, Bessis N.

Eur J Immunol. 2005 Dec;35(12):3704-13.

18.

Understanding the behavior of invariant NKT cells in autoimmune diseases.

Yamamura T, Sakuishi K, Illés Z, Miyake S.

J Neuroimmunol. 2007 Nov;191(1-2):8-15. Epub 2007 Oct 1. Review.

PMID:
17905445
19.

Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis.

Stanley AC, Zhou Y, Amante FH, Randall LM, Haque A, Pellicci DG, Hill GR, Smyth MJ, Godfrey DI, Engwerda CR.

PLoS Pathog. 2008 Feb 29;4(2):e1000028. doi: 10.1371/journal.ppat.1000028.

20.

[iNKT cells, a friend or a foe for autoimmune disease and allergy?].

Miyake S.

Nihon Rinsho Meneki Gakkai Kaishi. 2006 Feb;29(1):27-36. Review. Japanese.

Items per page

Supplemental Content

Write to the Help Desk